Gujarat Themis Biosyn: Sachin Patel to Acquire 0.50% Stake via Inter-se Promoter Transfer
Sachin D. Patel plans to acquire up to 5,25,000 equity shares of Gujarat Themis Biosyn Limited from Pharmaceutical Business Group (India) Limited between July 21-31, 2026. The acquisition, valued at up to ₹20 Crores at ₹382 per share, represents a 0.50% stake. This is an inter-se promoter transfer.
The acquisition involves a change in shareholding patterns within the promoter group, affecting the percentage ownership of specific entities. While it is an inter-se transfer and exempt from open offer, it alters the promoter group's structure and constitutes a substantial acquisition of shares.
The announcement details an inter-se transfer of shares among promoters, which is a common corporate action and does not inherently suggest a positive or negative development for the company's operations or financial performance.
Sachin D. Patel, a promoter of Gujarat Themis Biosyn Limited, intends to acquire up to 5,25,000 equity shares, representing approximately 0.50% of the total share capital, from Pharmaceutical Business Group (India) Limited. This transaction is an inter-se transfer among the promoter and promoter group.
The proposed acquisition is scheduled to take place between July 21, 2026, and July 31, 2026. The acquisition price is set at ₹382 per equity share, and the total value of the proposed acquisition is up to ₹20 Crores. The acquirer has declared that the acquisition price will not exceed 25% of the volume-weighted average market price for the preceding 60 trading days, which was ₹380.37 per equity share.
This disclosure is made in compliance with Regulation 10(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. An earlier disclosure made on July 1, 2026, for the same transaction could not be acted upon within the specified period and should be disregarded. Following the transaction, Sachin D. Patel's shareholding is expected to increase from 2.29% to 2.77%, while Pharmaceutical Business Group (India) Limited's shareholding will decrease from 47.02% to 46.54%.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.